Get the Stockscreener App
8.32
5.68%
-0.48
Rocket Pharmaceuticals Inc stock is traded at $8.32, with a volume of 375.25K.
It is down -5.68% in the last 24 hours and down -17.98% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
See More
Previous Close:
$8.80
Open:
$8.765
24h Volume:
375.25K
Relative Volume:
0.26
Market Cap:
$913.28M
Revenue:
-
Net Income/Loss:
$-258.08M
P/E Ratio:
-3.0255
EPS:
-2.75
Net Cash Flow:
$-202.32M
1W Performance:
-7.68%
1M Performance:
-17.98%
6M Performance:
-57.76%
1Y Performance:
-70.53%
1-Day Range:
$8.28
$8.795
1-Week Range:
$8.06
$9.11
52-Week Range:
$8.06
$28.73
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
8.345 | 913.28M | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.75 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
679.31 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.80 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.16 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.04 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
(RCKT) Investment Analysis and Advice - Stock Traders Daily
BMO Capital Initiates Coverage on Rocket Pharmaceuticals With Outperform Rating, $50 Price Target - Marketscreener.com
BMO Capital Initiates Coverage of Rocket Pharmaceuticals (RCKT) with Outperform Recommendation - Nasdaq
Rocket Pharmaceuticals: A Buy Rating for Its Pioneering Gene Therapy Approach and Promising Pipeline - TipRanks
Private Advisor Group LLC Acquires Shares of 13,199 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by New York State Common Retirement Fund - Defense World
Rhumbline Advisers Has $1.25 Million Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Research Analysts Set Expectations for RCKT FY2025 Earnings - Defense World
Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory - Insider Monkey
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
Handelsbanken Fonder AB Has $290,000 Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Cut to $15.00 by Analysts at The Goldman Sachs Group - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Raised to $52.00 at Scotiabank - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $36.00 at Canaccord Genuity Group - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 1-Year Low on Analyst Downgrade - Defense World
Rocket Pharmaceuticals Inc (NASDAQ: RCKT)’s Stock Adds 0.53%, Making It A Good Investment - Stocks Register
Scotiabank raises Rocket Pharmaceuticals target to $52 - Investing.com
What is William Blair’s Estimate for RCKT Q1 Earnings? - Defense World
Rocket Pharmaceuticals price target raised to $52 from $51 at Scotiabank - TipRanks
What is Leerink Partnrs’ Estimate for RCKT Q2 Earnings? - Defense World
Chardan Capital Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $54.00 - Defense World
Needham & Company LLC Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $42.00 - Defense World
Rocket Pharmaceuticals price target lowered to $15 from $29 at Goldman Sachs - MSN
When Will Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Turn A Profit? - Yahoo Finance Australia
Decoding Rocket Pharmaceuticals Inc (RCKT): A Strategic SWOT Ins - GuruFocus.com
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus - MSN
Rocket Pharmaceuticals Advances Gene Therapy Pipeline - TipRanks
Rocket Pharmaceuticals (NASDAQ:RCKT) Posts Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 12-Month LowHere's What Happened - MarketBeat
Promising Outlook for Rocket Pharmaceuticals: Buy Rating Reiterated with $32 Price Target - TipRanks
Rocket Pharmaceuticals Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Rocket Pharmaceuticals Rings the Opening Bell - Nasdaq
Cantor Fitzgerald cuts Rocket Pharmaceuticals target to $50 By Investing.com - Investing.com Canada
Rocket Pharmaceuticals price target lowered to $54 from $62 at Chardan - TipRanks
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Positive Outlook for Rocket Pharmaceuticals Amidst Regulatory Progress and Financial Stability - TipRanks
Rocket Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress - BioSpace
Rocket Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Rocket Pharmaceuticals: Q4 Earnings Snapshot -February 27, 2025 at 04:15 pm EST - Marketscreener.com
ROCKET PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Gene Therapy Pioneer Rocket Pharmaceuticals Secures Funding Through 2026 Despite Wider Losses - StockTitan
Rocket Pharmaceuticals Inc (RCKT) may enjoy gains as insiders got busy in the recent days - Knox Daily
Selling Rocket Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Simply Wall St
Rocket Pharmaceuticals Executives Cash Out: See Who Sold Big! - TipRanks
Rocket Pharmaceuticals (RCKT) Projected to Post Quarterly Earnings on Monday - Defense World
Long Term Trading Analysis for (RCKT) - Stock Traders Daily
2 Soaring Stocks to Hold for the Next 20 Years - The Globe and Mail
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Hits New 52-Week LowHere's Why - MarketBeat
Sovran Advisors LLC Acquires New Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rocket Pharmaceuticals Inc Stock (RCKT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schwartz Jonathan David | See Remarks |
May 17 '24 |
Sale |
23.35 |
2,754 |
64,306 |
169,659 |
| Schwartz Jonathan David | See Remarks |
Aug 16 '24 |
Sale |
18.50 |
2,710 |
50,135 |
166,949 |
| Schwartz Jonathan David | See Remarks |
Nov 21 '24 |
Sale |
13.05 |
3,097 |
40,416 |
163,852 |
| Patel Kinnari | See Remarks |
Feb 21 '25 |
Sale |
10.58 |
6,078 |
64,305 |
444,103 |
| Wilson Martin | General Counsel |
Feb 21 '25 |
Sale |
10.58 |
3,222 |
34,089 |
150,696 |
| Militello John | See Remarks |
Feb 21 '25 |
Sale |
10.58 |
2,737 |
28,957 |
65,757 |
| Shah Gaurav | CEO |
Feb 21 '25 |
Sale |
10.58 |
16,303 |
172,486 |
772,680 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):